Combination therapy for digestive tract cancer-related ascites
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a modified TNF drug (rmhTNF-NC), an immunotherapy (tislelizumab), and radiation therapy for people with digestive system cancers that have caused moderate or large amounts of fluid buildup in the belly (ascites) and when standard treatments have stopped working. The goal is to see if this approach can help control the ascites and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with a digestive system cancer (such as stomach, colon, or pancreatic) that has spread to the lining of your belly, causing fluid buildup (malignant ascites).
- You have moderate or large amounts of this belly fluid that either hasn't been treated before or has come back after other treatments.
- You have a large tumor mass in your belly (at least 5 cm) that can be targeted with radiation.
- You are generally well enough to care for yourself (ECOG score 0-2) and have adequate organ function (heart, lungs, blood counts, kidney, liver).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
This trial tests a drug called liposomal irinotecan, given alone or with other medications, to treat fluid buildup in the belly caused by digestive system cancers. It's for people who have already tried standard treatments without success.
This trial tests a new combination of treatments for stomach cancer that has spread to the lining of the abdomen. It uses an immunotherapy drug (tislelizumab) with chemotherapy (SOX) and heated chemotherapy directly into the abdomen (HIPEC) to see if it works better than standard care.
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
This trial tests a combination of low-dose radiation therapy, immunotherapy, and chemotherapy for people whose stomach or colon cancer has spread to the lining of the belly (peritoneal cavity). The goal is to see if this approach can help control the cancer.
Hear when a new Digestive System Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.